LULU vs PFE: Which Is the Better Buy?
Side-by-side comparison of Lululemon Athletica Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Lululemon Athletica Inc. · Consumer Cyclical
$111.77
+45.0% upside to fair value
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
LULU has more upside to fair value
(+45.0%).
LULU trades at a lower forward P/E
(9.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LULU |
PFE |
| Current Price |
$111.77 |
$25.22 |
| Fair Value Estimate |
$162.07 |
$25.92 |
| Upside to Fair Value |
+45.0%
|
+2.8%
|
| Market Cap |
$12.7B |
$143.7B |
| Forward P/E |
9.1x
|
19.2x
|
| EV / EBITDA |
5.1x
|
12.3x
|
| Price / Sales |
1.1x
|
2.3x
|
| Price / FCF |
9.9x
|
15.2x
|
| Revenue Growth YoY |
+4.3%
|
+5.4%
|
| Gross Margin |
55.7%
|
69.3%
|
| Operating Margin |
18.2%
|
23.4%
|
| Return on Equity |
31.3%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
10.08%
|
6.6%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Lululemon Athletica Inc. operates in the premium athletic apparel retail sector, leveraging a strong brand and a durable competitive moat driven by product innovation and global expansion, particularly in China. The company has demonstrated solid capital allocation with organic growth and buybacks, though it faces near-term earnings pressure with a 38% decline in quarterly earnings year-over-year…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
LULU |
PFE |
| Zone Low |
$121.55 |
$19.44 |
| Zone High |
$137.76 |
$22.03 |
| In Buy Zone? |
Yes
|
No
|